Mammary Cell News Volume 8.35 | Sep 08 2016

TOP STORY

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

ESR1 mutations are selected by prior aromatase inhibitor therapy in advanced breast cancer. Researchers assessed the impact of ESR1 mutations on sensitivity to standard therapies in two Phase III randomized trials that represent the development of the current standard therapy for estrogen receptor–positive advanced breast cancer. [J Clin Oncol] Abstract | Press Release

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Overcoming Resistance to HER2 Inhibitors Through State-Specific Kinase Binding

Scientists identified an inhibitor of the active HER2–HER3 oncogenic complex, they developed a panel of Ba/F3 cell lines suitable for ultra-high-throughput screening. [Nat Chem Biol] Abstract

High Cell-Surface Density of HER2 Deforms Cell Membranes

Investigators found HER2 overexpression causes deformation of the cell membranes, and this in turn disrupts epithelial features by perturbing cell–substrate and cell–cell contacts. [Nat Commun] Full Article

Aurora a Kinase Activates YAP Signaling in Triple-Negative Breast Cancer

Scientists determined that Aurora A kinase acts as a positive regulator for Yes-associated protein (YAP)-mediated transcriptional machinery. [Oncogene] Abstract

Neratinib Induces ErbB2 Ubiquitylation and Endocytic Degradation via HSP90 Dissociation in Breast Cancer Cells

HER2 positive is a major type of breast cancer for which ErbB2 targeting is already proving to be an effective therapeutic strategy. Investigators report the effects of lapatinib and neratinib on the mRNA and protein levels of the ErbB2 receptor. [Cancer Lett] Abstract

Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors

Scientists demonstrated that aqueous two-phase system spheroids recapitulate important biological and functional properties of solid tumors and provide a unique model for studies in cancer research. [Adv Healthc Mater] Abstract

Statins Affect ETS1-Overexpressing Triple-Negative Breast Cancer Cells by Restoring DUSP4 Deficiency

The authors investigated the molecular mechanisms underlying statin-induced growth suppression of triple-negative breast cancer (TNBC) that overexpress the transcription factor ets proto-oncogene 1 (ets-1) and downregulate dual specific protein phosphatase 4 (dusp4) expression. [Sci Rep] Full Article

Phosphorylation of Calcium/Calmodulin-Stimulated Protein Kinase II at T286 Enhances Invasion and Migration of Human Breast Cancer Cells

Researchers demonstrated that calcium/calmodulin-stimulated protein kinase II (CaMKII) expression and phosphorylation at T286 is increased in breast cancer when compared to normal breast tissue, and that increased CAMKII mRNA is associated with poor breast cancer patient prognosis.They showed that overexpression of WT, T286D and T286V forms of CaMKII in MDA-MB-231 and MCF-7 breast cancer cells increases invasion, migration and anchorage independent growth, and that overexpression of the T286D phosphomimic leads to a further increase in the invasive, migratory and anchorage independent growth capacity of these cells. [Sci Rep] Full Article

RACK1 Stabilises the Activity of PP2A to Regulate the Transformed Phenotype in Mammary Epithelial Cells

RACK1 has been identified as a key regulator downstream of growth factor and adhesion signaling and as a direct binding partner of PP2A. Scientists sought to further characterize the interaction between PP2A and RACK1 and to advance the understanding of this complex in breast cancer cells. [Cell Signal] Abstract

Deregulation of the Hippo Pathway in Mouse Mammary Stem Cells Promotes Mammary Tumorigenesis

Researchers examined the role of the Hippo-YAP pathway in the development of mouse mammary glands and tumor formation using gland reconstitution by transplantation of genetically modified mammary stem cells. [Mamm Genome] Abstract

CLINICAL RESEARCH

Prognostic Factors for Local Control in Breast Cancer After Long-Term Follow-Up in the EORTC Boost vs No Boost Trial a Randomized Clinical Trial

The EORTC “boost no boost” trial showed that young age and high-grade invasive carcinoma were the most important risk factors for ipsilateral breast tumor recurrence (IBTR). Scientists re-analyzed pathological prognostic factors related to IBTR using long-term follow-up. [JAMA Oncol] Abstract | Press Release

On Metabolic Reprograming and Tumor Biology: A Comprehensive Survey of Metabolism in Breast Cancer

the authors review and compile currently known aspects of breast cancer biology into a comprehensive network, elucidating previously dissonant issues of cancer metabolism. [Oncotarget] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Oncocyte to Present Initial Data on Its Breast Cancer Diagnostic Test at the Prestegious San Antonia Breast Cancer Symposium

OncoCyte Corporation announced that its breast cancer abstract has been selected for presentation in a poster session, at the 2016 San Antonio Breast Cancer Symposium. [Press release from OncoCyte Corporation discussing research presented at San Antonio Breast Cancer Symposium, San Antonio, TX] Press Release

GTx Achieves Stage 1 Milestone in Phase II Clinical Trial of Enobosarm in ER+/AR+ Breast Cancer

GTx, Inc. announced the achievement of the Stage 1 milestone for the 9 mg cohort of its Phase II clinical trial of enobosarm (GTx-024) to treat women with advanced, estrogen receptor positive (ER+), androgen receptor positive (AR+) breast cancer. [GTx, Inc.] Press Release

AACR Launches 2017 NextGen Grants for Transformative Cancer Research

The American Association for Cancer Research (AACR) announced the launch of the second round of its flagship grant program, the AACR NextGen Grants for Transformative Cancer Research. [American Association for Cancer Research] Press Release

Cancer Experts Unveil Wishlist for US Government 'Moonshot'

Advisers to the US Cancer Moonshot Initiative have produced a wide-ranging laundry list of research targets for the project — even as its funding remains uncertain. The ten recommendations released on 7 September include the launch of a national clinical-trial network specifically targeted at therapies that harness the immune system, and the creation of a 3D cancer atlas to catalogue how a tumour interacts with neighbouring normal cells. [Nature News] Editorial

US Science Agencies Face Budget Limbo

Another year, another round of budget roulette for US science agencies. When Congress returns from its summer break on 6 September, it will have just three weeks to pass a new government funding bill before the 2017 budget year begins on 1 October. Policy analysts predict that lawmakers will pass a stopgap funding measure that will keep agencies’ budgets flat until the presidential election in November — and perhaps into next year. [Nature News] Editorial

In Wake of Attacks, German Science Bodies Fend for Animal Research

Germany's major research institutes have teamed up to publicly defend “responsible” animal testing as a necessary part of biomedical science. [Science News] Editorial

Boom in Unproven Cell Therapies Intensifies Regulatory Debate

Controversial US guidelines attempt to rein in rogue stem-cell clinics. [Nature News] Editorial

NEW World Advanced Therapies & Regenerative Medicine Congress 2017
May 17-19, 2017
London, United Kingdom

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position or Internship – Cancer Research (Stanford University)

NEW Postdoctoral Researcher – Nuclear Medicine Dosimetry (University of Oxford)

Postdoctoral Fellow – Rho GTPase Signaling in the Process of Breast Cancer (University of Leeds)

Faculty Pathologist – Breast Pathology (University of California Los Angeles)

Postdoctoral Researcher – Breast Cancer (Purdue University)

Robert Stowell Chair – Experimental Pathology (University of California, Davis)

Postdoctoral Associate – Bioinformatics of Colorectal and Triple Negative Breast Cancer (University of Miami)

Scientific Director – Oncology (Merck)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization's career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.